Adicet Bio, Inc.
No enriched coverage for $ACET in the last 7 days.
No SEC Form 4 filings for $ACET in the last 30 days.
See all $ACET insider activity →Adicet Bio received FDA clearance to start a Phase 1 trial for ADI-212, an experimental cell therapy for advanced prostate cancer. The company plans to enroll patients in the final quarter of 2026. ADI-212 is an off-the-shelf therapy designed to target PSMA protein on prostate-cancer cells, with added modifications to enhance effectiveness against solid tumors.
Adicet Bio, Inc. (ACET) filed an SEC Form 8-K — Results of Operations and Financial Condition. Adicet Bio Reports Second Quarter 2026 Financial Results and Provides Business Updates Company to provide a comprehensive Phase 1 clinical update for prulacabtagene leucel (prula-cel, formerly ADI-001), featuring data from 22 patients with lupus nephritis (LN) and systemic lupus
Adicet Bio, Inc. (ACET) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. 8-K false 0001720580 0001720580 2026-06-17 2026-06-17 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 17,
Recent ACET coverage spans financial news, regulation and earnings.
Adicet Bio received FDA clearance to start a Phase 1 trial for ADI-212, an experimental cell therapy for advanced prostate cancer. The company plans to enroll patients in the final quarter of 2026. ADI-212 is an off-the-shelf therapy designed to target PSMA protein on prostate-cancer cells, with added modifications to enhance effectiveness against solid tumors.
Near-term catalyst is the 3Q/2026 prula-cel clinical update, with additional regulatory and enrollment milestones for ADI-212 later in 2026.
Routine corporate governance disclosure; provides confirmation of board composition and shareholder sentiment on executive compensation.
Major shareholder Ra Capital Management increased its stake in Adicet Bio by approximately 7.19%, purchasing an additional 74,268 shares at an average price of $7.21. This insider activity suggests a positive outlook on the company's valuation.
Adicet Bio Inc (ACET) is expected to report a significant loss of $2.80 per share, indicating potential short-term negative sentiment and price decline.
alphai scores every news story that mentions ACET with an AI model for sentiment and relevance, and aggregates insider trades from Adicet Bio, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Adicet Bio received FDA clearance to start a Phase 1 trial for ADI-212, an experimental cell therapy for advanced prostate cancer. The company plans to enroll patients in the final quarter of 2026. ADI-212 is an off-the-shelf therapy designed to target PSMA protein on prostate-cancer cells, with added modifications to enhance effectiveness against solid tumors.
1 min readAdicet Bio, Inc. (ACET) filed an SEC Form 8-K — Results of Operations and Financial Condition. Adicet Bio Reports Second Quarter 2026 Financial Results and Provides Business Updates Company to provide a comprehensive Phase 1 clinical update for prulacabtagene leucel (prula-cel, formerly ADI-001), featuring data from 22 patients with lupus nephritis (LN) and systemic lupus
6 min readAdicet Bio, Inc. (ACET) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. 8-K false 0001720580 0001720580 2026-06-17 2026-06-17 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 17,
2 min readRa Capital Management, L.P., a major shareholder in Adicet Bio (NASDAQ:ACET), recently increased its stake by purchasing 74,268 shares for $535,472.28 at an average cost of $7.21 per share. This transaction, occurring on February 19th, increased their total holdings to 1,107,873 shares, representing a 7.19% increase in their position. Other recent purchases by Ra Capital Management in February include 74,751 shares at $7.27 and 74,577 shares at $7.04.
4 min readAdicet Bio Inc (ACET) is projected to report a loss of $2.80 per share in its upcoming earnings. This earnings preview provides a brief financial outlook for the company based on Refinitiv data.
3 min readThe average one-year price target for Adicet Bio (ACET) has significantly increased by 1,210.53% to $101.59 per share, up from the prior estimate of $7.75. This revised target is an average of analyst estimates ranging from $18.18 to $151.20, representing an 1,125.48% increase from its last closing price of $8.29. Institutional ownership in ACET remains high at 72 funds, holding 52,987K shares, and a bullish put/call ratio of 0.07.
2 min readAdicet Bio Inc. ( NASDAQ:ACET ) shares fell Tuesday after the biotechnology company priced an $80 million direct offering, even as early safety and efficacy data from its Phase 1 trial of ADI-001 in autoimmune diseases showed encouraging signs.
3 min readHere is how Exact Sciences (EXAS) and Adicet Bio, Inc. (ACET) have performed compared to their sector so far this year.
4 min readAdicet Bio (ACET) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
3 min readAdicet Bio (ACET) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
2 min read
